Does retatrutide lower blood pressure?
In trials, yes: a meta-analysis found retatrutide lowered systolic blood pressure by a weighted mean of 6.79 mmHg and diastolic by 2.46 mmHg.
GLP-1 / GIP / glucagon triple agonistUpdated
Short answer
In trials, yes: a meta-analysis found retatrutide lowered systolic blood pressure by a weighted mean of 6.79 mmHg and diastolic by 2.46 mmHg.[1]
Where the numbers come from and the flip side
A review of phase 2 data cites an 8.79 mm Hg reduction in systolic blood pressure alongside improved urine albumin-to-creatinine ratio.[2]
In the phase 3 trial in type 2 diabetes, hypotension was reported in 1%, 5% and 6% of the 4, 9 and 12 mg groups against under 1% on placebo.[3]
The phase 2 obesity trial separately reported dose-dependent heart-rate increases that peaked at 24 weeks and declined afterwards.[4]
More questions on Retatrutide
More on Retatrutide
Sources
- 1Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026
- 2Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.Cardiology in review · 2026PMID 42108533Accessed 2 Oct 2026
- 3Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
- 4Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
Found an error? Report a correction.